TY - JOUR
T1 - NCCN Guidelines ® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
AU - Benson, Al B.
AU - Venook, Alan P.
AU - Al-Hawary, Mahmoud M.
AU - Cederquist, Lynette
AU - Chen, Yi Jen
AU - Ciombor, Kristen K.
AU - Cohen, Stacey
AU - Cooper, Harry S.
AU - Deming, Dustin
AU - Engstrom, Paul F.
AU - Garrido-Laguna, Ignacio
AU - Grem, Jean L.
AU - Grothey, Axel
AU - Hochster, Howard S.
AU - Hoffe, Sarah
AU - Hunt, Steven
AU - Kamel, Ahmed
AU - Kirilcuk, Natalie
AU - Krishnamurthi, Smitha
AU - Messersmith, Wells A.
AU - Meyerhardt, Jeffrey
AU - Miller, Eric D.
AU - Mulcahy, Mary F.
AU - Murphy, James D.
AU - Nurkin, Steven
AU - Saltz, Leonard
AU - Sharma, Sunil
AU - Shibata, David
AU - Skibber, John M.
AU - Sofocleous, Constantinos T.
AU - Stoffel, Elena M.
AU - Stotsky-Himelfarb, Eden
AU - Willett, Christopher G.
AU - Wuthrick, Evan
AU - Gregory, Kristina M.
AU - Freedman-Cass, Deborah A.
N1 - Publisher Copyright:
©© JNCCN-Journal JNCCN-Journal of of the the National National Comprehensive Comprehensive Cancer Cancer Network Network
PY - 2018/4/1
Y1 - 2018/4/1
N2 - The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.
AB - The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.
KW - Colonic Neoplasms/diagnosis
KW - Humans
UR - http://www.scopus.com/inward/record.url?scp=85045662724&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000429534300005&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2018.0021
DO - 10.6004/jnccn.2018.0021
M3 - Comment/debate
C2 - 29632055
SN - 1540-1405
VL - 16
SP - 359
EP - 369
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 4
ER -